←
Profluent192 posts
Profluent avatar

Profluent

@ProfluentBio

Grounded in nature, authored by AI

◷ Joined September 2022▧ 89 Photos and videos
Profluent avatar
Profluent@ProfluentBio·19 Nov 2025

Today we’re announcing $106M in new funding led by Altimeter Capital and Bezos Expeditions. This brings our total to $150M to scale our frontier AI models which make biology programmable. Our frontier models have generated functional proteins (Nature Biotech, 2023), created the first CRISPR system designed from scratch (Nature, 2025), and showed clear scaling behavior (NeurIPS spotlight, 2025). The opportunities ahead are unimaginable. If you’re excited by shaping the future of biology – join us in pushing the science forward. Forbes: forbes.com/sites/amyfeldman/… Press Release: businesswire.com/news/home/2… -- Nature Biotech, 2023: nature.com/articles/s41587-0… NeurIPS spotlight, 2025: biorxiv.org/content/10.1101/… Nature, 2025: nature.com/articles/s41586-0…

0:08
Profluent avatar
Profluent@ProfluentBio·Nov 16

AI company 🤝 life sciences award Last week, @CALifeSciences named Profluent its 2026 Emerging Innovator of the Year! Our frontier AI models design and optimize proteins, right here in Emeryville. Thank you to the CLS team, and congratulations to all the honorees!

Post attachmentPost attachment
Profluent avatar
Profluent@ProfluentBio·Oct 12

Profluent is a finalist for the Emerging Innovator of the Year award at the 23rd Annual Pantheon Awards @CALifeSciences Frontier AI for biology, built in California.

Meet the 2026 Pantheon Award winners 🏆🌊 Through their transformative discoveries, breakthrough technologies, and steadfast leadership, this group of innovators, companies, and institutions have advanced California's life sciences industry and made exceptional contributions to improve lives around the world. We're looking forward to honoring @Genentech, Ziad Obermeyer, MD, @NOETIK_ai, @RevMedicines, Teal Health, @SD2org, and Catriona Jamieson, MD, PhD, this November. 🌟 Plus, we'll be announcing the winner of our Emerging Innovator of the Year award live during the ceremony. Join us in San Francisco and be the first to find out who it is 🔗 bit.ly/4jd7S0n

0:30
Ali Madani avatar
⟳ Profluent retweeted
Ali Madani@thisismadani·Sep 30

we build foundation models that span all protein modalities (ie not just one type of medicine). this partnership with @BioMarin pharma is one piece of evidence towards that. we'll have even more announcements soon on this point

We’re partnering with @BioMarin to use our AI models to design novel medicines. Our foundation models unlock proteins with new and improved functions by drawing on the world's largest dataset of unique protein sequences (115B and counting): Profluent’s Protein Atlas BioMarin will screen designs we generate and advance the strongest into preclinical testing. Looking forward to what AI can unlock for patients!

Post attachment
BioMarin avatar
⟳ Profluent retweeted
BioMarin@BioMarin·Sep 30

We’re excited to be partnering with @ProfluentBio, an innovative AI lab for biology that will apply its foundational AI models to generate novel enzyme therapies for BioMarin. Profluent will design and optimize potential medicines using the largest protein sequence dataset in the world, composed of more than 115 billion unique sequences. Our scientists will screen these protein designs and evaluate the most promising candidates to advance to preclinical models, accelerating our early stage research and development in metabolic conditions. Read more: ms.spr.ly/6013aYRXN

0:21
Profluent avatar
Profluent@ProfluentBio·Sep 30

We’re partnering with @BioMarin to use our AI models to design novel medicines. Our foundation models unlock proteins with new and improved functions by drawing on the world's largest dataset of unique protein sequences (115B and counting): Profluent’s Protein Atlas BioMarin will screen designs we generate and advance the strongest into preclinical testing. Looking forward to what AI can unlock for patients!

Post attachment
Profluent avatar
Profluent@ProfluentBio·Aug 12

Stephen Nayfach, our Head of Bioinformatics and Platform R&D, is at @CSHL this week for the Genome Engineering: CRISPR Frontiers event. Find him and say hi if you're there! 👋 He's giving a talk on using our AI models to design CRISPR-Cas9 variants for base editing ("Programming PAM Specificity for Mutation-Specific Base Editor Design") and also chairing the session "CRISPR Technologies I"

Post attachmentPost attachment
Richard Shuai avatar
⟳ Profluent retweeted
Richard Shuai@richardwshuai·Jul 31

Heading to Summer RosettaCon next week to share my work from my time at @ProfluentBio Come listen to my talk about the encoder model Profluent-E1 on Thur at 1:30pm (“E1: Retrieval-Augmented Protein Encoders for Fitness and Structure Prediction”) and let’s chat after!

Profluent avatar
Profluent@ProfluentBio·Jul 30

The Profluent team is heading to Summer RosettaCon next week! Find @jeffruffolo, @richardwshuai, @ShiakiMinami, and Alex Hoffnagle and say hi 👋 You can hear Richard talk about E1, our encoder model, on Thur at 1:30pm (“E1: Retrieval-Augmented Protein Encoders for Fitness and Structure Prediction”) and Alex share his work on our AI-designed base editors on Mon at 7:30pm (“Design of Programmable Base Editors with Protein Language Models”).

Post attachment
Ali Madani avatar
⟳ Profluent retweeted
Ali Madani@thisismadani·Jul 9

The government is backing us for a moonshot to design *personalized curative* medicines. Excited to be partnering with GemmaBio and be in the elite company of the best medical centers in the world. Each word has significance. Personalized = bespoke to each patient [this is where programmable biology with AI can directly play a role] Curative = lasting solutions that cure not just manage disease. This is what we at Profluent live for, real cures to disease. Let's go build!

Post attachment
Profluent avatar
Profluent@ProfluentBio·Jul 9

A suite of AI-designed base editors, all from one scaffold. The only piece unique to each patient is the guide RNA. That's the shift AI unlocks: rare disease moves from 'one drug at a time' to a platform, built to bring cost down and reach more patients. More on our work with GEMMABio, now backed by @ARPA_H's THRIVE program, below.

Post attachment
Profluent avatar
Profluent@ProfluentBio·Jul 9

The bottleneck in rare disease is design: too many mutations, one editor at a time. AI unlocks that. Proud to be building GemmaBio's platform with them under @ARPA_H 's THRIVE program. We're bringing our frontier AI models and base editors to the work to design modular gene editors that scale across many mutations.

95% of rare diseases have no approved treatment. When your child is getting sicker, waiting isn’t an option. ARPA-H is investing $160 million through THRIVE to accelerate personalized genetic cures for the kids who need them most. A rare diagnosis should never mean no hope for a cure. @broadinstitute @ChildrensPhila @igisci @StJude @Stanford #GEMMABio #MassachusettsGeneralHospital arpa-h.gov/news-and-events/a…